{"id":"sodium-hexacyclonate","rwe":[{"pmid":"13878809","year":"1962","title":"Adjunctive treatment of the chronic alcoholic with hexacyclonate sodium.","finding":"","journal":"The Illinois medical journal","studyType":"Clinical Study"},{"pmid":"13692926","year":"1961","title":"[Sodium hexacyclonate as coadjuvant in the treatment and rehabilitation of the chronic alcoholic].","finding":"","journal":"Minerva medica","studyType":"Clinical Study"}],"tags":[{"label":"hexacyclonate sodium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"repriscal","offLabel":[],"synonyms":["hexacyclonate sodium","1-(Hydroxymethyl)cyclohexaneacetic acid","repriscal","hexacyclonic acid","sodium hexacyclonate"],"timeline":[],"approvals":[],"brandName":"Repriscal","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"hexacyclonate sodium","explanation":"As a result, it is difficult to explain how Repriscal works in simple terms. However, in general, small molecule drugs like Repriscal are designed to interact with specific biological targets, such as proteins or receptors, to produce a therapeutic effect. This interaction can lead to changes in the body's normal functioning, which can help to treat a particular disease or condition.","oneSentence":"Unfortunately, the mechanism of action of Repriscal is unknown.","technicalDetail":"Repriscal's mechanism of action is currently unknown, and further research is necessary to determine its pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3459","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sodium hexacyclonate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:38:56.870596","biosimilars":[],"competitors":[],"genericName":"sodium hexacyclonate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6XI46H39BZ","CHEBI":"CHEBI:134805","INN_ID":"947","UMLSCUI":"C0219131","ChEMBL_ID":"CHEMBL2106201","PUBCHEM_CID":"23675742","SECONDARY_CAS_RN":"7491-42-1","MESH_SUPPLEMENTAL_RECORD_UI":"C082676"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1962 May","pmid":"13878809","title":"Adjunctive treatment of the chronic alcoholic with hexacyclonate sodium.","journal":"The Illinois medical journal"},{"date":"1961 Jun 20","pmid":"13692926","title":"[Sodium hexacyclonate as coadjuvant in the treatment and rehabilitation of the chronic alcoholic].","journal":"Minerva medica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Repriscal, also known as sodium hexacyclonate, is a small molecule drug in the hexacyclonate sodium class. However, due to the lack of available information, there is no comprehensive summary of its mechanism of action, target, or approved indications. As a result, Repriscal's commercial status, safety considerations, and pharmacokinetic properties remain unknown. Further research is necessary to understand the properties and potential applications of Repriscal. Unfortunately, the available data does not provide a clear picture of this compound's characteristics.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}